SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

anti-TNBC agent-1

Cat. No.: HY-145143

CAS No.: 2289585-58-4

Molecular Formula: $C_{26}H_{30}O_7$

Molecular Weight: 454.51

Target: Apoptosis

Pathway: Apoptosis

Storage: -20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (110.01 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2002 mL	11.0009 mL	22.0017 mL
	5 mM	0.4400 mL	2.2002 mL	4.4003 mL
	10 mM	0.2200 mL	1.1001 mL	2.2002 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

anti-TNBC agent-1 is a potent anti-triple-negative breast cancer (TNBC) agent. anti-TNBC agent-1 exhibits potent activity against different breast cancer cells with IC_{50} values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 induces apoptosis of SUM-159 cells through mitochondria pathway and causes G1 phase arrest of SUM-159 cells[1].

In Vitro

anti-TNBC agent-1 (compound 7) exhibits potent activity against MDA-MB231, SUM-159, MCF-7, Bcap-37, 4T1 cells with IC_{50} values ranging from 0.20 μM to 0.27 μM. anti-TNBC agent-1 shows 11.6- to 18.6-fold improvement comparing to that of the parent compound parthenolide with IC50 values of 2.68-4.63 μM. anti-TNBC agent-1 is more active than the positive control drug Adriamycin (ADR)[1].

anti-TNBC agent-1 (2 μM and 5 μM; 48 hours; SUM-159 cells) exhibits significant stronger effect on induction of cell apoptosis compared with that of Parthenolide[1].

anti-TNBC agent-1 has selective cytotoxicity against breast cancer cells (IC_{50}=0.22 μM) being compared with 3T3 cells (IC_{50} =8.13 μM)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ge W, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445-469.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA